Literature DB >> 33575350

Intratumoral STING Agonist Injection Combined with Irreversible Electroporation Delays Tumor Growth in a Model of Hepatocarcinoma.

Aritz Lasarte-Cia1, Teresa Lozano1, David Cano2, Celia Martín-Otal1, Flor Navarro1, Marta Gorraiz1, Noelia Casares1, Isabel Vivas2, Juan José Lasarte1.   

Abstract

BACKGROUND/AIM: Irreversible electroporation (IRE) showed promising results for small-size tumors and very early cancers. However, further development is needed to evolve this procedure into a more efficient ablation technique for long-term control of tumor growth. In this work, we show that it is possible to increase the antitumor efficiency of IRE by simmultaneously injecting c-di-GMP, a STING agonist, intratumorally.
MATERIALS AND METHODS: Intratumoral administration of c-di-GMP simultaneously to IRE was evaluated in murine models of melanona (B16.OVA) and hepatocellular carcinoma (PM299L).
RESULTS: The combined therapy increased the number of tumor-infiltrating IFN-γ/TNF-α-producing CD4 and CD8 T cells and delayed tumor growth, as compared to the effect observed in groups treated with c-di-GMP or IRE alone.
CONCLUSION: These results can lead to the development of a new therapeutic strategy for the treatment of cancer patients refractory to other therapies.
Copyright © 2021 Aritz Lasarte-Cia et al.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33575350      PMCID: PMC7857890          DOI: 10.1155/2021/8852233

Source DB:  PubMed          Journal:  Biomed Res Int            Impact factor:   3.411


  44 in total

1.  Angiography in the isolated perfused kidney: radiological evaluation of vascular protection in tissue ablation by nonthermal irreversible electroporation.

Authors:  Johann Jakob Wendler; Maciej Pech; Simon Blaschke; Markus Porsch; Andreas Janitzky; Matthias Ulrich; Oliver Dudeck; Jens Ricke; Uwe-Bernd Liehr
Journal:  Cardiovasc Intervent Radiol       Date:  2011-06-02       Impact factor: 2.740

Review 2.  Locoregional Therapy, Immunotherapy and the Combination in Hepatocellular Carcinoma: Future Directions.

Authors:  Meaghan S Dendy; Johannes M Ludwig; Stacey M Stein; Hyun S Kim
Journal:  Liver Cancer       Date:  2019-01-16       Impact factor: 11.740

3.  Percutaneous Ablation of Hepatic Tumors Using Irreversible Electroporation: A Prospective Safety and Midterm Efficacy Study in 34 Patients.

Authors:  Christoph Niessen; Lukas P Beyer; Benedikt Pregler; Marco Dollinger; Benedikt Trabold; Hans J Schlitt; Ernst M Jung; Christian Stroszczynski; Philipp Wiggermann
Journal:  J Vasc Interv Radiol       Date:  2016-02-26       Impact factor: 3.464

4.  Single-center nonrandomized clinical trial to assess the safety and efficacy of irreversible electroporation (IRE) ablation of liver tumors in humans: Short to mid-term results.

Authors:  P Frühling; A Nilsson; F Duraj; U Haglund; A Norén
Journal:  Eur J Surg Oncol       Date:  2017-01-11       Impact factor: 4.424

5.  STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors.

Authors:  Seng-Ryong Woo; Mercedes B Fuertes; Leticia Corrales; Stefani Spranger; Michael J Furdyna; Michael Y K Leung; Ryan Duggan; Ying Wang; Glen N Barber; Katherine A Fitzgerald; Maria-Luisa Alegre; Thomas F Gajewski
Journal:  Immunity       Date:  2014-11-05       Impact factor: 31.745

6.  Safety and feasibility of Irreversible Electroporation (IRE) in patients with locally advanced pancreatic cancer: results of a prospective study.

Authors:  Salvatore Paiella; Giovanni Butturini; Isabella Frigerio; Roberto Salvia; Giulia Armatura; Matilde Bacchion; Martina Fontana; Mirko D'Onofrio; Enrico Martone; Claudio Bassi
Journal:  Dig Surg       Date:  2015-02-28       Impact factor: 2.588

7.  Irreversible electroporation in locally advanced pancreatic cancer: potential improved overall survival.

Authors:  Robert C G Martin; Kelli McFarland; Susan Ellis; Vic Velanovich
Journal:  Ann Surg Oncol       Date:  2012-11-06       Impact factor: 5.344

8.  Type I interferon is selectively required by dendritic cells for immune rejection of tumors.

Authors:  Mark S Diamond; Michelle Kinder; Hirokazu Matsushita; Mona Mashayekhi; Gavin P Dunn; Jessica M Archambault; Hsiaoju Lee; Cora D Arthur; J Michael White; Ulrich Kalinke; Kenneth M Murphy; Robert D Schreiber
Journal:  J Exp Med       Date:  2011-09-19       Impact factor: 14.307

Review 9.  The cGAS-cGAMP-STING pathway connects DNA damage to inflammation, senescence, and cancer.

Authors:  Tuo Li; Zhijian J Chen
Journal:  J Exp Med       Date:  2018-04-05       Impact factor: 14.307

View more
  4 in total

Review 1.  Electroporation and Immunotherapy-Unleashing the Abscopal Effect.

Authors:  Tobias Freyberg Justesen; Adile Orhan; Hans Raskov; Christian Nolsoe; Ismail Gögenur
Journal:  Cancers (Basel)       Date:  2022-06-10       Impact factor: 6.575

Review 2.  Intratumoral Immunotherapy and Tumor Ablation: A Local Approach with Broad Potential.

Authors:  Zachary J Senders; Robert C G Martin
Journal:  Cancers (Basel)       Date:  2022-03-30       Impact factor: 6.639

3.  Intratumoral electroporation of a self-amplifying RNA expressing IL-12 induces antitumor effects in mouse models of cancer.

Authors:  Noelia Silva-Pilipich; Aritz Lasarte-Cía; Teresa Lozano; Celia Martín-Otal; Juan José Lasarte; Cristian Smerdou
Journal:  Mol Ther Nucleic Acids       Date:  2022-07-20       Impact factor: 10.183

Review 4.  Irreversible Electroporation: An Emerging Immunomodulatory Therapy on Solid Tumors.

Authors:  Nana Zhang; Zhuoqun Li; Xuan Han; Ziyu Zhu; Zhujun Li; Yan Zhao; Zhijun Liu; Yi Lv
Journal:  Front Immunol       Date:  2022-01-07       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.